<DOC>
	<DOCNO>NCT00724048</DOCNO>
	<brief_summary>The purpose study determine ACR16 effective safe symptomatic treatment Huntington 's Disease .</brief_summary>
	<brief_title>A Study Pridopidine ( ACR16 ) Treatment Patients With Huntington 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Able provide write Informed Consent prior study related procedure , include consent genotyping CYP2D6 gene . Clinical feature HD , positive family history and/or presence ≥ 36 CAG repeat Huntington gene . Male female age ≥ 30 year . Willing able take oral medication comply study specific procedure . Ambulatory , able travel assessment center , judge Investigator likely able continue travel duration study . Availability caregiver family member accompany subject two visit . A sum ≥ 10 point mMS screening visit . For subject take allowed antidepressant psychotropic medication , dose medication must keep constant least 6 week enrollment . Treatment antipsychotic medication ( neuroleptic ) within 8 week enrollment , time point study period . Use tetrabenazine within 12 week enrollment , time study period . Treatment investigational product within 4 week enrollment . Use tricyclic antidepressant class I antiarrhythmics within 6 week enrollment , time study period . Use concomitant medication may lower seizure threshold within 6 week enrollment , time study period . Use metoclopramide within 12 week enrollment , time study period . Subjects currently receive deep brain stimulation ( DBS ) . Subjects history surgical procedure aim improve symptom Huntington disease , neural transplantation , lesion central nervous system , infusion neurotrophic agent previous attempt deep brain stimulation . Subjects previously randomize study . A prolonged QTc interval Screening Visit ( define QTc interval &gt; 450 msec male &gt; 470 msec female ) , clinically significant heart condition judge investigator . Creatinine clearance &lt; 40mL/min measure screening visit . Any clinically significant , abnormal , baseline laboratory result opinion Investigator , affect subject ' suitability study put subject risk he/she enters study . Clinically significant hepatic renal impairment . Subjects know history epilepsy history febrile seizure ( ) seizure ( ) unknown cause . Severe intercurrent illness , , opinion Investigator , may put subject risk participate trial may influence result trial affect subject ' ability take part trial . Alcohol and/or drug abuse define DSM IVTR criterion Substance Abuse include illicit use cannabis within last 12 month prior Screening Visit Subjects suicidal ideation define positive score criterion major depressive episode , item A9 DSM IVTR criterion Major Depressive Episode Females pregnant lactate intend become pregnant study period . Females child bear potential take adequate contraceptive precaution exclude trial . ( Females child bear potential take acceptable contraceptive precaution include ) Known allergy ingredient trial medication placebo Any previous participation clinical study ACR16 .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Huntington Disease</keyword>
</DOC>